1. |
|
|
2. |
- Astermark, Jan, et al.
(author)
-
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
- 2010
-
In: Haemophilia. - : Wiley. - 1351-8216. ; May 4, s. 747-766
-
Journal article (peer-reviewed)abstract
- Summary. The development of inhibitors to the infused factor in patients with haemophilia is a serious clinical problem. Recent evidence suggests that alongside the strong genetic contribution to inhibitor formation, there are a number of non-genetic factors - perceived by the immune system as danger signals - which promote formation of inhibitors. This study provides a comprehensive review of clinical studies relating to these factors and also presents a survey of opinion concerning their importance and clinical influence, conducted among the members of the European Haemophilia Treatment Standardisation Board (EHTSB). Taken together, this information highlights the lack of robust data concerning the influence of several non-genetic risk factors on inhibitor development, and an urgent need for prospective, well-conducted studies that adhere to recommendations made by the European Medicines Agency (EMEA) for studying inhibitors. Based on current literature, the EHTSB formulated consensus recommendations. It is desirable to minimize intensive treatment wherever possible, given the clinical situation. Prophylaxis should be offered to all children, although we still need to determine optimal dosing with respect to inhibitor development, and age for starting treatment. Vaccinations should be given subcutaneously and concomitant factor concentrate infusions avoided. According to the board, there is no evidence in the literature supporting suggestions that the type of concentrate influences inhibitor risk; but all patients should be monitored during their first exposures. Furthermore, there is no evidence to support an association between pregnancy-related issues, breast feeding and treatment-related factors (e.g. route of administration, or use of blood components) and inhibitor development.
|
|
3. |
- Kaiser, M., et al.
(author)
-
VEDLIoT: Very Efficient Deep Learning in IoT
- 2022
-
In: Proceedings of the 2022 Design, Automation and Test in Europe Conference and Exhibition, DATE 2022. - : IEEE. - 9783981926361
-
Conference paper (peer-reviewed)abstract
- The VEDLIoT project targets the development of energy-efficient Deep Learning for distributed AIoT applications. A holistic approach is used to optimize algorithms while also dealing with safety and security challenges. The approach is based on a modular and scalable cognitive IoT hardware platform. Using modular microserver technology enables the user to configure the hardware to satisfy a wide range of applications. VEDLIoT offers a complete design flow for Next-Generation IoT devices required for collaboratively solving complex Deep Learning applications across distributed systems. The methods are tested on various use-cases ranging from Smart Home to Automotive and Industrial IoT appliances. VEDLIoT is an H2020 EU project which started in November 2020. It is currently in an intermediate stage with the first results available.
|
|
4. |
- Astermark, Jan, et al.
(author)
-
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
- 2006
-
In: Haemophilia. - : Wiley. - 1351-8216 .- 1365-2516. ; 12:4, s. 363-371
-
Journal article (peer-reviewed)abstract
- The management of patients with inhibitors is an important challenge in haemophilia care. The lack of randomized controlled trials means that clinical decisions are generally based on subjective opinions, and purchasers' attention is likely to focus on the costs of treatment. In order to assess the current management of inhibitor patients and use of immune tolerance induction therapy (ITI) in Europe, we performed a survey within a European network of 21 comprehensive care centres from 14 countries (the European Haemophilia Therapy Standardisation Board). The survey identified a total of 381 patients with inhibitors attending the centres, 211 (55.4%) of whom had never been exposed to ITI. Between 1998 and 2003, the centres performed 233 procedures and 114 (48.9%) were successful. The survey demonstrated that dosing, which is the time to start and stop the ITI, the type of concentrate to use and the definition of success varied among the centres. Well-designed trials are warranted to guide decision-making, but in the absence of these studies we have developed consensus guidance for the management of inhibitor patients based on current clinical practice, as identified by the survey, and review of the literature.
|
|
5. |
- Astermark, Jan, et al.
(author)
-
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
- 2007
-
In: Haemophilia. - : Wiley. - 1351-8216 .- 1365-2516. ; 13:1, s. 38-45
-
Journal article (peer-reviewed)abstract
- The ultimate goal of treatment for patients with inhibitory antibodies should be to permanently eradicate the inhibitor by immune tolerance induction therapy (ITI). However, ITI procedures fail in a substantial number of patients and in many countries ITI is not even offered owing to its high cost. How patients with inhibitors are managed in different European countries is evaluated with a special focus on the use of by-passing agents, i.e. recombinant FVIIa (rFVIIa) and activated prothrombin complex concentrates (aPCC), as well as the type of monitoring performed. Investigators from 22 large haemophilia centres participating within the network of the European Haemophilia Therapy Standardisation Board (EHTSB) were asked to complete a questionnaire. rFVIIa was routinely used in all centres for both children and adults at dosages ranging from 90 to 250 mu g kg(-1) at an interval of 2-4 h. aPCC was used in 85% of the centres in adults and in 25% of the centres in children with haemophilia A at dosages of 50-100 IU kg(-1) every 6-12 h. The corresponding figures for children and adults with haemophilia B were 40% and 15% of the centres, respectively. Higher dosages of both agents were considered in the case of life-threatening bleeds. General recommendations were developed, based on the information provided by the survey. The results clearly indicate the need for well-designed comparative studies to optimize the use of by-passing agents.
|
|
6. |
- Salami, B., et al.
(author)
-
LEGaTO: Low-Energy, Secure, and Resilient Toolset for Heterogeneous Computing
- 2020
-
In: PROCEEDINGS OF THE 2020 DESIGN, AUTOMATION & TEST IN EUROPE CONFERENCE & EXHIBITION (DATE 2020). - 1530-1591. - 9783981926347 ; , s. 169-174
-
Conference paper (peer-reviewed)abstract
- The LEGaTO project leverages task-based programming models to provide a software ecosystem for Made in-Europe heterogeneous hardware composed of CPUs, GPUs, FPGAs and dataflow engines. The aim is to attain one order of magnitude energy savings from the edge to the converged cloud/HPC, balanced with the security and resilience challenges. LEGaTO is an ongoing three-year EU H2020 project started in December 2017.
|
|
7. |
|
|
8. |
|
|
9. |
- Ménétrey, J., et al.
(author)
-
Attestation Mechanisms for Trusted Execution Environments Demystified
- 2022
-
In: <em>Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)</em>. - Cham : Springer Science and Business Media Deutschland GmbH. - 9783031160912 ; , s. 95-113
-
Conference paper (peer-reviewed)abstract
- Attestation is a fundamental building block to establish trust over software systems. When used in conjunction with trusted execution environments, it guarantees the genuineness of the code executed against powerful attackers and threats, paving the way for adoption in several sensitive application domains. This paper reviews remote attestation principles and explains how the modern and industrially well-established trusted execution environments Intel SGX, Arm TrustZone and AMD SEV, as well as emerging RISC-V solutions, leverage these mechanisms.
|
|
10. |
|
|